Synergy CHC Corp Dossier - Source-backed chat

Synergy CHC Corp

SNYRNASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.76

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.09Price as of 17 Sep 2026

Data confidenceNot applicable

Market Cap $1.3M

Shares Outstanding 14.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Synergy CHC Corp. (NASDAQ: SNYR) is navigating a critical operational and financial transition. While its legacy nutraceutical and online segments (such as Flat Tummy) face severe headwinds from out-of-stock issues and the non-recurrence of high-margin licensing revenues, its newly launched functional beverage division under the FOCUSfactor brand is showing strong early momentum, operating at an annualized run rate exceeding $4 million. However, the company is highly leveraged, carrying a $17.5 million term loan with high interest rates, and faces substantial going concern risks alongside a Nasdaq minimum bid price deficiency. Investors should maintain a Hold stance to monitor whether the beverage segment's growth can offset legacy declines and if capital-raising initiatives can stabilize the balance sheet.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.75

Mean target$3.75

High · most bullish analyst$3.75

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0520%

The company fails to regain compliance with Nasdaq's minimum bid price requirement, leading to delisting and a severe loss of liquidity. Dilution from the ELOC and ATM programs severely depresses per-share metrics, and high interest expenses on its $17.5 million term loan exhaust remaining cash reserves, forcing a restructuring or bankruptcy.

Base CaseCentral scenario

$0.3055%

Beverage sales grow steadily but legacy nutraceutical and online sales remain sluggish due to persistent supply chain and inventory challenges. The company manages to raise enough capital to meet short-term obligations but remains highly leveraged with compressed margins, trading near its current depressed levels as it works through its restructuring.

Bull CaseUpside scenario

$1.5025%

The functional beverage division continues its rapid expansion across North America, securing major retail wins and exceeding its $4 million annualized run rate. The company successfully utilizes its ELOC and ATM programs to shore up liquidity, and stockholders approve a reverse stock split that successfully cures the Nasdaq minimum bid price deficiency without causing catastrophic dilution.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong early momentum in the functional beverage segment, which generated over $650,000 in Q1 2026, surpassing its entire FY2025 performance.
Established retail distribution footprint for flagship brands FOCUSfactor and Flat Tummy through major club, mass drug, and online retailers.
Active international expansion, including recent entry into the Mexican market and planned expansion into Taiwan, Asia, and Australia.

Key Investment Risks

Severe liquidity constraints, highlighted by a working capital deficit of $503,862 and cash reserves of only $292,115 as of March 31, 2026.
High leverage and debt service costs, driven by a $17.5 million term loan carrying a high interest rate (~14.25%), resulting in over $2 million in quarterly interest expenses.
Nasdaq delisting risk due to non-compliance with the $1.00 minimum bid price requirement.
Significant potential dilution from equity incentive plan expansions, lender warrants, and the $36 million ELOC agreement.

Thesis Invalidation Triggers

Delisting of the common stock from the Nasdaq Capital Market.
Failure of the functional beverage segment to maintain its annualized run rate above $4 million.
Inability to secure additional working capital or restructure the $17.5 million term loan.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.